Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus CLINDETS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus CLINDETS.
BENSULFOID vs CLINDETS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It also acts as a competitive inhibitor of bacterial ribosomal RNA methyltransferases.
Bensulfoid: not a recognized drug. No data available.
Clindamycin: 150-450 mg orally every 6 hours; 600-900 mg IV every 8 hours. Max: 1.8 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is 2.4-3 hours in adults; prolonged to 4-6 hours in severe hepatic impairment.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Approximately 10% of the dose is excreted unchanged in urine; the remainder is hepatically metabolized and eliminated via bile (fecal: ~40%) and urine as inactive metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic